MarketWatchBiogen stock plummets 28% after company halts Alzheimer’s trialsMar 25, 2019bookmark_bordersharemore_vert
CNNAnother promising Alzheimer's drug trial ends in failure: 'This one hurts'Mar 21, 2019Sandee LaMotteBy Sandee LaMottebookmark_bordersharemore_vert
CNBCBiogen posts its the worst day in 14 years after ending trial for blockbuster Alzheimer's drugMar 21, 2019Yun LiBy Yun Libookmark_bordersharemore_vert
STATBiogen halts studies of closely watched Alzheimer's drug, a blow to hopes for new treatmentMar 21, 2019Adam FeuersteinBy Adam Feuersteinbookmark_bordersharemore_vert